Neuroscience company Cognivue, Inc has named Karen Parkyn-Michael as vice president of marketing and strategy. She brings more than 25 years of experience in leading strategic and commercial excellence for several multinational medical device organizations, including Boston Scientific, Smith and Nephew, Sanofi, and Olympus Corporation of America, according to the company’s announcement. Prior to joining Cognivue, Parkyn-Michael was vice president of global marketing for private equity-backed Z-Medica.
Cognivue President and CEO Tom O’Neill said, “We are excited to welcome Karen to the Cognivue team. She has a proven history of building global growth strategies and executing plans that maximize success. Her innovative approach in an always changing healthcare environment is exactly what Cognivue needs to further accelerate our momentum.”
In her new position, Parkyn-Michael is responsible for all product and company marketing, positioning, and customer communications while building, managing, and coaching an expanding team. Her position also includes oversight of defining and advocating for the brain health patient care continuum to improve access and care.
Parkyn-Michael said, “I am grateful to Tom O’Neill and his team for extending this exciting opportunity. The collaborative, entrepreneurial environment at Cognivue allows me to use my experience in the medical device field in new and creative ways. Innovation is a critical part of my work and Cognivue is the perfect place for this next chapter. I look forward to leading a marketing team built on trust and high standards driving toward our goal of increased growth.”
Parkyn-Michael holds a Bachelor of Science degree in Business Administration from Millersville University.
About Cognivue, Inc
Cognivue, Inc is a neuroscience company focusing on cognitive health with “the world’s first FDA-cleared computerized test of cognitive function.” The Cognivue device and technology are based on years of research that uses adaptive psychophysics to focus on cortical information processing by testing cognitive domains. The technology “significantly improves the ability of healthcare providers to implement a personalized assessment of cognitive function in a wide variety of care settings.”